This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Comment: Celgene pipeline cancer drug could raise eyebrows in Bristol-Myers deal

By Flavia Fortes and Jenna Ebersole ( January 30, 2019, 18:01 GMT | Comment) -- Celgene has the rights to a liver cancer drug in the development pipeline that would compete with Bristol-Myers Squibb’s Opdivo, potentially creating an antitrust problem given signs of growing FTC resistance to allowing pipeline drug divestitures. The company is partnering with China’s BeiGene to develop the drug, and the terms of their agreement indicate Celgene could sell its stake if necessary. But it remains unclear whether the FTC would accept that divestiture.Celgene has the rights to a liver cancer drug in the development pipeline that would compete with Bristol-Myers Squibb’s Opdivo, potentially creating an antitrust problem given signs of growing FTC resistance to allowing pipeline drug divestitures....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login